Skip to main content
Yabao Pharmaceutical Group Co.,Ltd logo

Yabao Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600351 ISIN · CNE000001CM5 LEI · 65560071PKRS4UHMVU53 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,360 across all filing types
Latest filing 2025-11-12 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600351

About Yabao Pharmaceutical Group Co.,Ltd

http://www.yabao.com.cn

Yabao Pharmaceutical Group Co.,Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceutical products. The company maintains a specialized portfolio across therapeutic areas including pediatrics, cardiovascular health, and endocrinology. Key offerings include traditional Chinese medicines, chemical drugs, and innovative transdermal patches, such as the Dinggui Erqi Patch. The organization operates integrated production bases and research facilities dedicated to advancing drug delivery systems and biotechnological applications. Its business model emphasizes the modernization of traditional therapies alongside the development of conventional pharmaceuticals to address diverse clinical needs.

Recent filings

Filing Released Lang Actions
亚宝药业集团股份有限公司关于取得特殊医学用途配方食品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a special medical food registration certificate. It details the product name, registration number, approval authority, and some market context. There is no financial data, no mention of a report being attached or published, and no indication of a meeting or voting results. The document is a regulatory announcement about a product certification, which does not fit into financial reports or meeting materials. It is a regulatory announcement about a company event or approval, best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2025-11-12 Chinese
亚宝药业集团股份有限公司关于控股股东进行股票质押式回购交易的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding a stock pledge transaction by the controlling shareholder of the company. It details the number of shares pledged, the pledge start and end dates, the pledgee, and the purpose of the financing. There is no financial statement, earnings data, or management discussion. The document is a regulatory announcement about share pledge activity, which fits the category of Transaction in Own Shares (POS) as it relates to share pledging and financing activities involving company shares. The document length is short and it is not a report or a certification, so it is not RNS or RPA. Therefore, the best classification is POS with high confidence.
2025-11-03 Chinese
亚宝药业集团股份有限公司关于以集中竞价交易方式回购股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from 亚宝药业集团股份有限公司 regarding the progress of its share repurchase program conducted via centralized bidding. It details the number of shares repurchased, the price range, total amount spent, and the purpose of the repurchase (to reduce registered capital). The document references the initial repurchase plan approved at the 2024 annual general meeting and provides updates on the repurchase progress as of October 31, 2025. The content is focused on the company's buyback activity and does not contain financial statements or earnings data. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers share repurchase announcements and progress updates.
2025-11-03 Chinese
亚宝药业集团股份有限公司关于回购股份比例达到1%暨回购进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from 亚宝药业集团股份有限公司 regarding the progress of its share repurchase program. It details the percentage of shares repurchased (1.14%), the number of shares, the price range, and the total amount spent. It references the company's board approval and compliance with regulatory rules for share buybacks. The document is not a full financial report but a specific update on the company's share repurchase activity. Therefore, it fits the category of 'Transaction in Own Shares' (POS). The document length is short and focused solely on share repurchase progress, confirming it is not a full report or announcement of a report publication.
2025-10-30 Chinese
亚宝药业集团股份有限公司董事及高级管理人员离职管理制度
Governance Information Classification · 95% confidence The document is titled '董事及高级管理人员离职管理制度' which translates to 'Management System for the Resignation of Directors and Senior Management'. It details policies and procedures related to the resignation, duties, responsibilities, and shareholding restrictions of directors and senior management personnel. There is no financial data, no mention of financial results, no regulatory filings or announcements of voting results, no audit or legal proceedings information. The content is focused on governance and internal management rules regarding board and senior management personnel. This fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-10-24 Chinese
亚宝药业集团股份有限公司2025年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2025 Third Quarter Report" of 亚宝药业集团股份有限公司, indicating it is a quarterly financial report. It contains detailed financial statements including balance sheets, profit and loss statements, and cash flow statements for the third quarter of 2025. The report includes unaudited financial data, key financial metrics, shareholder information, and explanations of financial changes. The length of the document (over 13,000 characters) and the presence of substantive financial data confirm it is a full interim/quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2025
2025-10-24 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.